Roy A - Search Results

1

Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers.

Osawa M, Hasegawa M, Bello A, Roy A, Hruska MW. Osawa M, et al. Among authors: roy a. Cancer Chemother Pharmacol. 2019 Apr;83(4):705-715. doi: 10.1007/s00280-019-03771-z. Epub 2019 Jan 21. Cancer Chemother Pharmacol. 2019. PMID: 30666395

2

Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis.

Roy A, Mould DR, Wang XF, Tay L, Raymond R, Pfister M. Roy A, et al. J Clin Pharmacol. 2007 Nov;47(11):1408-20. doi: 10.1177/0091270007307573. J Clin Pharmacol. 2007. PMID: 17962428

3

Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients.

Yoshitsugu H, Sakurai T, Ishikawa H, Roy A, Bifano M, Pfister M, Seriu T, Hiraoka M. Yoshitsugu H, et al. Among authors: roy a. Diagn Microbiol Infect Dis. 2011 May;70(1):91-100. doi: 10.1016/j.diagmicrobio.2010.12.009. Diagn Microbiol Infect Dis. 2011. PMID: 21513847 Clinical Trial.

4

Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.

Hong Y, Kowalski KG, Zhang J, Zhu L, Horga M, Bertz R, Pfister M, Roy A. Hong Y, et al. Among authors: roy a. Antimicrob Agents Chemother. 2011 Dec;55(12):5746-52. doi: 10.1128/AAC.00554-11. Epub 2011 Sep 19. Antimicrob Agents Chemother. 2011. PMID: 21930880 Free PMC article.

5

Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients.

Hasegawa M, Imai Y, Hiraoka M, Ito K, Roy A. Hasegawa M, et al. Among authors: roy a. J Pharmacokinet Pharmacodyn. 2011 Dec;38(6):803-32. doi: 10.1007/s10928-011-9221-5. Epub 2011 Oct 15. J Pharmacokinet Pharmacodyn. 2011. PMID: 22002809 Clinical Trial.

6

Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma.

Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Feng Y, et al. Among authors: roy a. Clin Cancer Res. 2013 Jul 15;19(14):3977-86. doi: 10.1158/1078-0432.CCR-12-3243. Epub 2013 Jun 5. Clin Cancer Res. 2013. PMID: 23741070

7

Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma.

Feng Y, Masson E, Dai D, Parker SM, Berman D, Roy A. Feng Y, et al. Among authors: roy a. Br J Clin Pharmacol. 2014 Jul;78(1):106-17. doi: 10.1111/bcp.12323. Br J Clin Pharmacol. 2014. PMID: 24433434 Free PMC article. Clinical Trial.

8

Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab.

Agrawal S, Waxman I, Lambert A, Roy A, Darbenzio R. Agrawal S, et al. Among authors: roy a. Cancer Chemother Pharmacol. 2016 Mar;77(3):635-41. doi: 10.1007/s00280-016-2980-3. Epub 2016 Feb 10. Cancer Chemother Pharmacol. 2016. PMID: 26861469 Clinical Trial.

9

Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma.

Gibiansky L, Passey C, Roy A, Bello A, Gupta M. Gibiansky L, et al. Among authors: roy a. J Pharmacokinet Pharmacodyn. 2016 Jun;43(3):243-57. doi: 10.1007/s10928-016-9469-x. Epub 2016 Mar 18. J Pharmacokinet Pharmacodyn. 2016. PMID: 26993283

10

Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.

Luo M, Chapel S, Sevinsky H, Savant I, Cirincione B, Bertz R, Roy A. Luo M, et al. Among authors: roy a. Antimicrob Agents Chemother. 2016 May 23;60(6):3676-86. doi: 10.1128/AAC.02678-15. Print 2016 Jun. Antimicrob Agents Chemother. 2016. PMID: 27067333 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,153 results

Search Page

Filters